First, a previously identified issue relates to the potential for sex-specific differences when investigating long-term outcomes (2). There is strong evidence that prenatal exposure to both SSRIs and maternal depression is associated with a variety of sex-specific outcomes, including postnatal growth (2). We have previously investigated the effect of prenatal SSRI exposure on risk for children who are overweight at 4–5 years old. In this study, we observed that girls of SSRI-exposed mothers were less likely to be overweight compared with girls of mothers with an untreated psychiatric illness (adjusted prevalence ratio, 0.23; 95% confidence interval [CI]=0.05–0.98) and girls of unexposed mothers (adjusted prevalence ratio, 0.27; 95% CI=0.07–0.99). In contrast, no association with being overweight was observed among boys of exposed mothers compared with boys of mothers with an untreated psychiatric illness (adjusted prevalence ratio, 1.17; 95% CI=0.54–2.51) and boys of unexposed mothers (adjusted prevalence ratio, 0.93; 95% CI=0.52–1.67) (3). It would be useful to know whether any analyses were undertaken to examine potential interactions between exposure and the child’s sex and if so, if any differences were observed.